E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis
- First Online:
Multiple studies examining the relationship between loss of E-cadherin expression, a pivotal event for evolving metastatic behavior among epithelially derived cancers, and 5-year survival in infiltrating ductal breast carcinoma have yielded inconclusive and contradictory results.
We conducted a systematic review of the PubMed database through August 2005 with no language restrictions to identify cohort studies that evaluated E-cadherin immunohistochemical expression as a prognostic marker for ductal breast carcinoma. 5-year all-cause mortality or 5-year breast cancer-specific mortality were the primary study outcomes. Meta-analysis was conducted using the REVMAN software and summary hazard ratios assuming both fixed effect and random effect models were calculated.
Ten retrospective cohort studies were identified. Reduced or absent E-cadherin expression significantly increased the risk of all-cause mortality [combined HR = 1.55; 95% CI = 1.08–2.23] whereas a non-significant association was observed for breast cancer-specific mortality [combined HR = 0.70; 95% CI = 0.39–1.27]. We documented substantial inter-study heterogeneity with respect to all aspects of clinical data collection, immunohistochemical staining and interpretation as well as statistical modeling. These factors could not be formally analyzed but they challenge the robustness of our calculated summary estimates.
Loss of E-cadherin expression may be an independent negative prognostic indicator for infiltrating ductal breast carcinoma and randomized, controlled studies evaluating this finding are justified. We encourage standardization of immunohistochemical techniques, data interpretation algorithms across laboratories and use of all-cause mortality to increase data compatibility and facilitate future efforts summarizing the utility of alternate prognostic markers in cancer.
Key wordsBreast cancer Cancer prognosis E-cadherin Immunohistochemistry Meta-analysis
Unable to display preview. Download preview PDF.
- 2.Wood WC, Muss HB, Solin LJ, Olopade OI (2005). Chapter 33: Cancer of the breast—Section 2: Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and practice of oncology, 7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1415–1477Google Scholar
- 3.Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O’Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116–128PubMedGoogle Scholar
- 4.van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRefGoogle Scholar
- 5.Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRefGoogle Scholar
- 11.Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson RI, Robertson JFR, Blamey RW, Ellis IO (1999) An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins and alpha2- and beta1-integrins in invasive breast cancer. J Pathol 187:523–529PubMedCrossRefGoogle Scholar
- 14.Jones JL, Royall JE, Walker RA (1996) E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma. Br J Cancer 74:1273–1241Google Scholar
- 23.Bankfalvi A, Terpe H-J, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle R-J, Boecker W (1999) Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumor progression: a comparative study with CD44. Histopathology 34:25–34PubMedCrossRefGoogle Scholar
- 24.Nakopoulou L, Gakiopoulou H, Kermapoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS (2000) c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favorable prognostic factors in invasive breast cancer. Histopathology 36:313–325PubMedCrossRefGoogle Scholar
- 30.Ugur Y, Sari O, Ugur O, Korkusuz P, Varoglu E, Arslan N, Gurcan N, Yildirim M, Sokmensuer C, Asan E, Aras T (2003) Lack of correlation between Tc-99m-sesta-MIBI uptake and cadherin expression in infiltrating ductal carcinoma as prognostic indicators. Ann Nucl Med 17:281–287PubMedCrossRefGoogle Scholar
- 34.Song ZC, Wang GL, Qi YX, Cui DC, Li Y (2001) Relationship between expression of multiple tumor suppressor (MTS1) and E-cadherin and metastasis of breast carcinoma. Ai Zheng 22:526–528Google Scholar
- 37.Elkhuizen PHM, Hermans J, Leer JWH, van de Vijver MJ (2001) Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastases. Int J Radiat Oncol Biol Phys 50:387–396PubMedCrossRefGoogle Scholar
- 51.Deeks JJ, Altman DG, Bradburn MJ (2001) Chapter 15: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG (eds) Systematic reviews in health care: meta-analysis in context. 2nd edn. BMJ Press, Cornwall UK, pp 285–312Google Scholar
- 57.McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184Google Scholar